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Abstract
Background: Caveolae play a significant role in disease phenotypes such as cancer, diabetes, bladder dysfunction,
and muscular dystrophy. The aim of this study was to elucidate the caveolin-1 (CAV1) protein expression in renal
cell cancer (RCC) and to determine its potential prognostic relevance.
Methods: 289 clear cell RCC tissue specimens were collected from patients undergoing surgery for renal tumors.
Both cytoplasmic and membranous CAV1 expression were determined by immunohistochemistry and correlated
with clinical variables. Survival analysis was carried out for 169 evaluable patients with a median follow up of 80.5
months (interquartile range (IQR), 24.5 - 131.7 months).
Results: A high CAV1 expression in the tumor cell cytoplasm was significantly associated with male sex (p = 0.04),
a positive nodal status (p = 0.04), and poor tumor differentiation (p = 0.04). In contrast, a higher than average (i.e.
> median) CAV1 expression in tumor cell membranes was only linked to male sex (p = 0.03). Kaplan-Meier analysis
disclosed significant differences in 5-year overall (51.4 vs. 75.2%, p = 0.001) and tumor specific survival (55.3 vs.
80.1%, p = 0.001) for patients with higher and lower than average cytoplasmic CAV1 expression levels, respectively.
Applying multivariable Cox regression analysis a high CAV1 protein expression level in the tumor cell cytoplasm
could be identified as an independent poor prognostic marker of both overall (p = 0.02) and tumor specific
survival (p = 0.03) in clear cell RCC patients.
Conclusion: Over expression of caveolin-1 in the tumour cell cytoplasm predicts a poor prognosis of patients with
clear cell RCC. CAV1 is likely to be a useful prognostic marker and may play an important role in tumour
progression. Therefore, our data encourage further investigations to enlighten the role of CAV1 and its function as
diagnostic and prognostic marker in serum and/or urine of RCC patients.
Background
Renal cell carcinoma (RCC) is a common urologic
tumor and accounts for about 3% of all human malig-
nancies. A significant increase in its incidence has been
observed during the last decades, and the annual mor-
tality-to-incidence ratio for RCC is considerably higher
than for other tumors of the genitourinary tract [1].
Tumor characteristics such as tumor stage and grade
seem to have limited value in predicting the clinical out-
come of individual patients as around 50% of patients
who undergo surgery with curative intent for less
advanced disease can be expected to develop a distant
recurrence. Moreover, RCC encompasses many histologi-
cal subtypes with distinct genetic and biologic features
that determine clinical course and outcome [2]. There-
fore, an increased understanding of genetic and biologic
changes could help to develop a valuable marker to
improve the individual therapeutic management and clin-
ical outcome of RCC.
An essential step in the formation of metastases is the
invasion of tumor cells into the extra cellular matrix. Cell
adhesion molecules and extra-cellular matrix proteins can
either support an increase or a decrease in the ability of
tumor cells to adhere to surrounding tissue. Caveolin-1
(CAV1) has been identified two decades ago; it has been
proposed to act as a tumor suppressor protein, inhibiting
the functional signaling activity of several proto-oncogenes
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and consequently disrupting the process of cellular trans-
formation [3-12]. Numerous follow-up studies designed to
test this hypothesis have contributed a myriad of evidence
suggesting that CAV1 may indeed possess tumor suppres-
sor capabilities. For instance, CAV1 mRNA and protein
expressions are down regulated in NIH-3T3 cells trans-
formed with several activated oncogenes, such as v-Abl,
Bcr-Abl, and H-Ras (G12V) [3,9]. Genetic evidence sup-
porting the role of CAV1 as a tumor suppressor has
emerged from gene mapping studies, which revealed that
the human CAV-1 gene maps to the long arm of human
chromosome 7 (7q31.1). However, a number of clinico-
pathologial studies have shown a positive correlation
between CAV1 over expression and advanced renal cell
cancer, metastasis and poor prognosis [13]. In addition,
these studies yielded variable and even contradicting
results in terms of over expression in different histological
subtypes [2].
The aim of this study was to elucidate the expression
of CAV1 in RCC and to determine its potential prog-
nostic relevance for patients with clear cell cancer.
Methods
Tissue specimens
The present study included 289 patients, who underwent
radical nephrectomy between 1979 and 1998 in the Hann-
over Medical School. The ethical committee of the institu-
tion approved the study. Tissue was obtained from
archival routine surgical specimens. The tissue samples
were selected by a pathologist and prepared from the pri-
mary tumor and arranged on tissue micro arrays (TMA)
as described previously [14]. Two pathologists evaluated
all specimens with respect to tumor stage, grade, and his-
tological subtypes. Tumour samples were classified pri-
marily according to UICC 1997 TNM tumour staging
system [15] and nuclear grading was based on the Fuhr-
man grading system [16]. Histological subtypes were
assessed according to the consensus classification of renal
cell neoplasia [17]. Data were collected by physicians and
data managers and subsequently maintained by a rela-
tional database.
Patients
The median age of the cohort was 60.4 years (SD ± 11.3
months). 159 patients were men (55%), and 130 patients
were women (45%). 8, 150, 115, and 16 presented with
pT1, pT2, pT3 and pT4 cancer, respectively. Tumour dif-
ferentiation showed that 50, 181, 21 suffered from G1, G2,
and G3/4 tumours. Furthermore, 29 patients presented
with lymph node and 55 patients with visceral metastasis.
In the majority of cases, data regarding the cancer-
specific long-term survival (CSS) were retrieved from
electronic patient charts. The duration of the follow-up
was calculated from date of surgery to the date of death
or last follow-up. Death was assessed as either cancer-
related or unrelated. Survival analysis was carried out
for 169 evaluable patients with complete follow-up data
and pathologically proven clear cell carcinoma of the
kidney. The follow up group (n = 169) exhibited a med-
ian follow-up period of 80.5 months (IQR, 24.5 - 131.7
months). At the time of the last follow-up examination,
80 of patients were alive, 63 patients had died from pro-
gressive RCC and 26 patients due to other causes.
Procedures
Expression of CAV1 was determined by immunohisto-
chemistry (IHC). The paraffin-embedded TMA samples
were deparaffinized, rehydrated and immersed in 3%
hydrogen peroxide solution to block endogenous peroxi-
dase activity. Antigen retrieval was accomplished by
microwave heating specimens in a 0.01 M citrate buffer
for 15 min. Biomarker expression was immunohistochemi-
cally detected by commercially available antibodies (CAV1
rabbit polyclonal anti-caveolin-1 dilution 1:100, Becton
Dickinson Biosciences, Franklin Lakes, NJ, USA). After 12
h of incubation the sections were washed in TBS and incu-
bated with a secondary biotinylated antibody (Vectastatin
Elite ABC Kit, Vector Laboratories, Inc., Burlingame, CA,
USA) for 60 min. and visualization using the DAB systems
according to the manufacturer’s instructions. Sections
were briefly rinsed in tap water, counterstained with
Mayer’s Haematoxylin solution and then mounted. For
negative control, the primary antibody was replaced by
non-immune serum. All tissue staining were assessed in a
blind study by two independent investigators (H.B and S.
W.).
The rabbit polyclonal anti-caveolin-1 from Becton
Dickinson Biosciences (Franklin Lakes, NJ, USA) recog-
nises both the a and b isoforms of caveolin-1 as assessed
by Western blotting. Negative controls run in parallel-
comprised sections where the primary antibody had
been omitted. Caveolin-1 staining of peripheral endothe-
lial cells and non-neoplastic tissue adjacent to the
tumour were used as the positive controls (also see
additional file 1, figure S1). In negative controls the pri-
mary antibody was omitted.
The expression of CAV1 was evaluated in the mem-
brane, cytoplasm and nucleus of the tumour cells. The
staining reaction was classified according to a semi-
quantitative IHC reference scale as previously described
[18-22]. Membranous CAV1 expression was scored
using the internal vascular endothelial cells as the posi-
tive control. Staining stronger than, equivalent to, or
weaker than the vascular endothelial cells was scored as
3, 2 and 1, respectively, and the absence of staining was
scored as 0 [13] (also see additional file 2, figure S2). In
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addition, cytoplasmic CAV1 staining stronger than,
equivalent to, or weaker than the vascular endothelial
cells was scored as 5, 3 and 1, respectively; and the
absence of staining was scored as 0. Furthermore, the
scores 4 and 2 describing staining partly classified as 5
and 3 and 3 and 1, respectively, were added. Adding the
stained area (1 = 0-5%, 2 = 6-25%, 3 = 26-50%, 4 = 51-
75% and 5 = 76-100%) a novel staining intensity score
was defined by multiplying the score with the stained
area. Given the absence of normative data on cell mem-
brane or cell cytoplasma staining intensity in the litera-
ture, values in our patient collective were dichotomized
using the median of observed distribution as the cut off.
Statistical analysis
The primary endpoints of this study were tumor specific
and overall-survival. Continuous variables were reported
as means and standard deviations (SD) for parametric
distributions or as medians and interquartile ranges
(IQRs) for nonparametric distributions. Kaplan-Meier
survival times were calculated, and subgroups were
compared by the log-rank test statistic. Multivariate Cox
regression models were used to assess the association
between survival and cell membrane as well as cytoplas-
mic CAV1 expression adjusted for different clinical and
patient covariates. The chi-square test and Fisher’s exact
test were conducted to assess associations between cell
membrane/cytoplasm and patient/tumor specific charac-
teristics. SPSS 17.0 was used for statistical assessment. P
values below 0.05 were considered significant in all
tests. All p values were two-sided.
Results
Correlation between patient characteristics and CAV1
expression
CAV1 expression was detected in the tumor cell cyto-
plasm of 242 (83.7%) and the tumor cell membrane of
232 (80.3%) patients with clear cell RCC. The median
staining intensity was 3 (range: 1-25, IQR: 1-9) for
tumor cell cytoplasm, and 3 (range: 1-15, IQR: 1-6) for
tumor cell membranes, respectively. CAV1 protein
expression in the tumor cell cytoplasm and cell mem-
brane correlated moderately but significantly (r = 0.52, p
< 0.001, Pearson). The cell nuclei were CAV1 negative
in all patients’ tumor specimens.
A high CAV1 expression in the tumor cell cytoplasm
was significantly associated with male sex (p = 0.044), a
positive nodal status (p = 0.042), and poor tumor differ-
entiation (p = 0.035; table 1). In contrast, a higher than
average (i.e. > median or > 3 intensity score) CAV1
expression in tumor cell membranes was only linked to
male sex (p = 0.03; table 2). There was no significant
correlation between CAV1 staining and patient age,
tumor stage, and visceral metastasis.
CAV1 expression predicts the clinical course
The calculated median five-year overall and tumor spe-
cific survival ratio of all 169 evaluable patients was
65.0% and 69.5% months, respectively.
With a median follow-up of 80.5 months (IQR, 24.5 -
131.7 months), a higher disease-related death rate was
observed among patients with higher-than-average cyto-
plasmic CAV1 levels (50.7% vs. 26.8%, p = 0.002, Fish-
er’s exact test). Moreover, Kaplan-Meier analysis
disclosed significant differences in overall and tumor
specific survival for patients with higher and lower than
average cytoplasmic CAV1 expression levels, respec-
tively. The calculated 5-year survival rates for patients
with high vs. low cytoplasmic CAV1 levels (i.e. staining
intensity 0-3 vs. ≥4) were 51.4% vs. 75.2% for overall
survival (p = 0.001, log rank) and 55.3% vs. 80.1% for
disease specific survival (p = 0.001, log rank), respec-
tively (Figures 1 and 2). Furthermore, tumor-specific
survival of patients with a CAV1 staining score of 4 or 5
(n = 19) in the tumor cell cytoplasm was significantly
shorter compared with that of patients with a score of
2-3 (n = 38) and even more 0-1 (n = 112) with 5-year
tumor specific survival rate of 26.3%, 60.0%, and 80.1%,
respectively (p < 0.001, Mantel-Cox; additional file 3,
figure S3).
In contrast, using univariate analysis, high membranous
CAV1 failed to significantly predict tumor associated
death rates during follow up (42.9% vs. 33.6%, p = 0.25,
Fisher’s exact test). Accordingly, neither overall nor
tumor specific Kaplan-Meier survival were significantly
associated with CAV1 expression located in the tumor
cell membranes (p = 0.41 and 0.24, respectively; Figures
3 and 4). Furthermore, tumor-specific survival of patients
with a CAV1 staining score of 2 or 3 (n = 50) in the
tumor cell membrane was slightly but insignificantly
shorter compared with that of patients with a score of 1
(n = 85) or 0 (n = 34) with a 5-year tumor specific survi-
val rate of 61.9%, 72.8%, and 72.7%, respectively (p =
0.56, Mantel-Cox; additional file 4, figure S4).
Applying multivariable Cox regression analysis, includ-
ing age, sex, stage, metastasis status, and tumor grade, in
contrast to CAV1 cell membrane expression (p = 0.51;
HR 1.17, 95% CI 0.73-1.87, and p = 0.34; HR 1.31, 95%
CI 0.75-2.30), a high CAV1 protein expression level in
the tumor cell cytoplasm could be identified as an inde-
pendent poor prognostic marker of both overall (p =
0.022; HR 1,74, 95% CI 1.08-2.80) and tumor specific
survival (p = 0.026; HR 1.95, 95% CI 1.08-3.51) in RCC
patients (table 3).
Discussion
Increased CAV1 expression has been reported to be asso-
ciated with progression of papillary carcinoma of the
thyroid, high-grade bladder cancer, poor prognosis of
Steffens et al. BMC Urology 2011, 11:25
http://www.biomedcentral.com/1471-2490/11/25
Page 3 of 10
pancreas cancer, and lymph node metastasis in esopha-
geal squamous cell carcinoma. Moreover, increased
CAV1 expression has been reported to be associated with
various pathological parameters, including higher
Gleason score in prostate cancer, lymph node metastasis
and positive surgical margins, and it has been shown to
be an independent prognostic marker for progression in
clinically localized prostate cancer [23]. These studies
Table 1 Association of different patient and tumor specific characteristics with CAV1 protein expression in the tumor
cytoplasm.
Variable CAV1 in tumor cytoplasm ≤ median CAV1 in tumor cytoplasm > median p-value Test
Age (mean; ± SD) 60.4 ± 11.5 years 59.3 ± 11.1 years 0.40 t-test
Sex 0.04 Fisher’s exact
female 79 (50.6%) 51 (38.3%)
male 77 (49.4%) 82 (61.7%)
Stage (TNM 2002) 0.54 Chi2
pT1 5 (3.2%) 3 (2.3%)
pT2 86 (55.1%) 64 (48.1%)
pT3 58 (37.2%) 57 (42.9%)
pT4 7 (4.5%) 9 (6.7%)
LN metastasis1 0.04 Fisher’s exact
pN0 78 (89.7%) 70 (77.8%)
pN+ 9 (10.3%) 20 (22.2%)
Pulmonal/visceral metastasis1 0.23 Fisher’s exact
M0 124 (82.7%) 93 (76.2%)
M+ 26 (17.3%) 29 (23.8%)
Grade 0.04 Chi2
G1 30 (21.6%) 20 (17.7%)
G2 103 (74.1%) 78 (69.0%)
G3/4 6 (4.3%) 15 (13.3%)
1 at time of renal surgery.
Abbreviations: CAV1 = caveolin 1, RCC = renal cell carcinoma, SD = standard deviation, LN = lymph node.
Table 2 Association of different patient and tumor specific characteristics with CAV1 protein expression in tumor
membranes.
Variable CAV1 in tumor membranes ≤ median CAV1 in tumor membranes > median p-value Test
Age (mean; ± SD) 59.9 ± 11.7 years 59.8 ± 10.8 years 0.99 t-test
Sex 0.03 Fisher’s exact
female 87 (50.3%) 43 (37.1%)
male 86 (49.7%) 73 (62.9%)
Stage (TNM 2002) 0.54 Chi2
pT1 4 (2.3%) 4 (3.4%)
pT2 91 (52.6%) 59 (50.9%)
pT3 66 (38.2%) 49 (42.2%)
pT4 12 (6.9%) 4 (3.4%)
LN metastasis1 1.00 Fisher’s exact
pN0 86 (83.5%) 62 (83.8%)
pN+ 17 (16.5%) 12 (16.2%)
Pulmonal/visceral metastasis1 0.54 Fisher’s exact
M0 133 (81.1%) 84 (77.8%)
M+ 31 (18.9%) 24 (22.2%)
Grade 0.28 Chi2
G1 30 (20.2%) 20 (19.4%)
G2 110 (73.8%) 71 (68.9%)
G3/4 9 (6.0%) 12 (11.7%)
1 at time of renal surgery.
Abbreviations: CAV1 = caveolin 1, RCC = renal cell carcinoma, SD = standard deviation, LN = lymph node.
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indicate that CAV1 functions as a tumor metastasis and
progression-promoting molecule. On the other hand,
CAV1 has also been implicated in the inhibition of can-
cer progression. For example, CAV1 expression is fre-
quently lost in colon cancer, ovarian cancer, lung cancer
and sarcoma [9,24-27]. Therefore, the physiological role
of CAV1 in cancer cells is quite complicated depending
e.g. on the type of cancer and the tumor origin. Several
studies using tissue microarry (TMA) and immunostain-
ing have shown similar associations between the
increased expression of CAV1 and clinicopathological
parameters in RCC as described in prostate cancer. A
major difference between prostate and kidney tissue is
that CAV1 is present at high levels in normal kidney tis-
sue independent of CAV1 levels in tumor tissue but not
in normal prostate tissue [23].
Several groups of investigators have studied the prog-
nostic significance of caveolin-1 protein expression.
Horiguchi et al. [28] reported that in clear cell RCC
patients increased caveolin-1 expressions also correlated
with tumor aggressiveness. Campbell et al. [13] also
described that higher caveolin-1 expression was corre-
lated with shorter survival in 69 patients with clear cell
histology.
Previously, we were able to show that CAV1 mRNA
expression is higher in RCC compared to normal renal
tissue and increases with tumour stage [29]. In the pre-
sent study, which until today is the largest study cohort
with a sufficient follow-up period, Caveolin 1 protein
expression was correlated with clinico-pathological para-
meters and survival in patients with clear cell RCC.
Kaplan-Meier analysis disclosed significant differences in
overall and tumor specific 5-year survival for patients
with higher and lower than average cytoplasmic CAV1
expression levels, i.e. 51.4% vs. 75.2% for overall survival
and 55.3% vs. 80.1% for disease specific survival,
Figure 1 Association between cytoplasmic CAV1 expression and clinical outcome in all patients (Kaplan-Meier; n = 169): The overall
survival of patients with a higher-than-average CAV1 expression in the tumor cell cytoplasm was significantly shorter compared with
that of patients lower CAV1 levels. 5-year survival rates were calculated at 51.4% and 75.2% (p = 0.001, Mantel-Cox).
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respectively. This supports the hypothesis that CAV1
plays a potential role in renal carcinogenesis or at least
RCC progression. In contrast, a study by Tamaskar et al.
with 22 RCC patients there was no correlation between
membranous or cytoplasmic caveolin-1 expression and
other clinical parameters, with membranous caveolin-1
expression being detected predominantly in clear cell
RCC. Mete et al. [30] studied 112 renal tumors with dif-
ferent histological subtypes also using polyclonal rabbit
antihuman CAV1 antibody and observed that staining
was mainly cytoplasmic in all tumor groups. Also
Campbell et al. [13] showed in that staining is predomi-
nantly found in the tumor cell cytoplasm of RCC
patients. We were able to confirm these results as
CAV1 expression was detected in the tumor cell cyto-
plasm of 242 (83.7%) and the cell membrane of 232
(80.3%) patients with clear cell RCC, the cell nuclei were
negative in all patients’ tumor specimens. Furthermore,
high CAV1 protein expression level in the tumor cell
cytoplasm could be identified as an independent poor
prognostic marker.
The reasons for these findings are still unclear, as
CAV1 expression would be expected to be mainly found
on the cell surface. Tahir et al. [31] where able to show
that in prostate cancer cell lines CAV1 is secreted in
response to androgens and glucocorticoids leading to
survival and clonal growth of these cells and thereby
contributing to their metastatic potential and androgen
insensitivity. Tahir et al was able to show that elevated
preoperative levels of serum CAV1 predicts decreased
time to cancer recurrence [32]. Adapted from these
results, one explanation for the cytoplasmatic expression
of CAV1 in clear cell RCC might be that within the
transformed cells, CAV1 is rerouted into the secretory
pathway of these cells, and that the cytoplasmatic CAV1
accumulation may contribute to the transformed
Figure 2 Association between cytoplasmic CAV1 expression and clinical outcome in all patients (Kaplan-Meier; n = 169): The tumor-
specific survival of patients with a higher-than-average CAV1 expression in the tumor cell cytoplasm was significantly shorter
compared with that of patients lower CAV1 levels. 5-year survival rates were calculated at 55.3% and 80.1% (p = 0.001, Mantel-Cox).
Steffens et al. BMC Urology 2011, 11:25
http://www.biomedcentral.com/1471-2490/11/25
Page 6 of 10
phenotype. Furthermore, Puyraimond et al. [33] have
shown that CAV1 interacts and potentiates the activity
of metalloproteinases; other studies have shown the
same effect on urokinase receptors leading to the con-
clusion that CAV1 may serve as an important intercellu-
lar signaling molecule that is capable of inducing
progression, invasiveness and vascularisation of renal
tumors.
A further important fact is that the etiology of most
cancers does not reflect alterations in a single gene, but
rather the functional loss or induction of a series of key
regulatory proteins that, in combination, disrupts the
normal regulation of the cell cycle and subsequently
leads to uncontrolled cell growth [34]. CAV1 has been
recognized to potentiate AKT activity in a variety of
model systems. Campbell et al. [35] revealed that when
CAV1 is co expressed with pAKT, pmTOR, pS6 or p4E-
BP1 within the primary tumor, time to relapse was
significantly reduced compared with when either of the
individual variables were expressed alone. They have
suggested that the co expression of CAV1 and activated
components of the AKT/mTOR pathway represents a
‘linked molecular signature’ that identifies patients with
localized RCC that are at high risk of developing meta-
static disease that warrants greater postoperative surveil-
lance. Evaluation of the expression status of both CAV1
and mTOR pathway components in these tumors may
help to predict tumor response to novel pathway speci-
fic therapies, hence allowing appropriate selection of
treatment for individual patients. Interestingly, CAV1
has been identified as a molecular target of bortezomib,
which has many molecular targets including proteins
related to apoptosis, growth signaling/cell cycle heat-
shock proteins, and the proteasome pathway. A Phase II
trial in patients with advanced RCC showed moderate
clinical efficacy for bortezomib [36].
Figure 3 Association between cell membrane CAV1 expression and clinical outcome in all patients (Kaplan-Meier; n = 169): The
overall survival of patients with a higher-than-average CAV1 expression in the tumor cell membrane did not significantly differ from
that of patients lower CAV1 levels. 5-year survival rates were calculated at 59.7% and 68.1% (p = 0.41, Mantel-Cox).
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Figure 4 Association between cell membrane CAV1 expression and clinical outcome in all patients (Kaplan-Meier; n = 169): The
tumor-specific survival of patients with a higher-than-average CAV1 expression in the tumor cell membrane did not significantly
differ from that of patients lower CAV1 levels. 5-year survival rates were calculated at 64.4% and 72.5% (p = 0.24, Mantel-Cox).
Table 3 Multivariable Cox regression analysis identified an elevated CAV1 staining value in the tumor cytoplasm as an
independent predictor of tumor specific survival.
CAV1 expression in the tumor cell cytoplasm CAV1 expression in the tumor cell membrane
Variable HR (95% CI) p-value HR (95% CI) p-value
Age 1.01 (0.99-1.01) 0.35 1.01 (0.98-1.03) 0.71
Sex 0.45 0.44
female 1 (Reference) 1 (Reference)
male 1.26 (0.70-2.28) 1.27 (0.69-2.23)
T-Stage 0.43 0.19
pT1 1 (Reference) 1 (Reference)
pT2 1.43 (0.19-10.86) 0.73 1.43 (0.19-10.92) 0.73
pT3 2.28 (0.30-17.58) 0.43 2.64 (0.35-20.28) 0.35
pT4 2.97 (0.27-33.25) 0.38 3.39 (0.30-37.89) 0.32
Metastatic disease < 0.001 < 0.001
N/M0 1 (Reference) 1 (Reference)
N/M+ 5.04 (2.66-9.54) 4.88 (2.60-9.16)
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Conclusion
We were able to show that caveolin-1 protein expres-
sion is a predictor of poor disease-free survival in clear
cell RCC, suggesting that cell signaling pathways invol-
ving caveolin-1 may be of importance in tumor progres-
sion. Furthermore, the strength of the association with
poor prognosis suggests that CAV1 is likely to be a use-
ful prognostic marker. Therefore, our data encourage
further investigations to enlighten the role of CAV1 in
tumour progression and to assess its function as prog-
nostic marker for clinical use in serum and/or urine.
Additional material
Additional file 1: Figure S1. Caveolin-1 staining of peripheral
endothelial cells was used as the positive controls. With no staining
reaction of the membrane, cytoplasm and nucleus of the tumor cells.
Additional file 2: Figure S2. Strong membranous Caveolin-1 expression.
Additional file 3: Figure S3. Association between cytoplasmic CAV1
expression and clinical outcome in all patients (Kaplan-Meier; n = 169)
focusing on the individual cellular maximum staining score: The tumor-
specific survival of patients with a CAV1 staining score of 4 or 5 (n = 19)
in the tumor cell cytoplasm was significantly shorter compared with that
of patients with a score of 2-3 (n = 38) and even more 0-1 (n = 112). 5-
year tumor specific survival rate were calculated at 26.3%, 60.0%, and
80.1% (p < 0.001, Mantel-Cox).
Additional file 4: Figure S4. Association between cell membrane CAV1
expression and clinical outcome in all patients (Kaplan-Meier; n = 169)
focusing on the individual cellular maximum staining score: The tumor-
specific survival of patients with a CAV1 staining score of 2 or 3 (n = 50)
in the tumor cell membrane was slightly but insignificantly shorter
compared with that of patients with a score of 1 (n = 85) or 0 (n = 34).
5-year tumor specific survival rate were calculated at 61.9%, 72.8%, and
72.7% (p = 0.56, Mantel-Cox).
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